Study wrapper · #26
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Editor's note
This narrative review from Frontiers in Aging maps nine therapeutic peptides across aging-related domains — metabolic function, telomere biology, tissue repair, neuroprotection, GH modulation, and sexual function. The authors drew on 20 primary sources selected from PubMed, Scopus, and regulatory databases through January 2026.
The core finding is an evidence stratification most readers of this space already sense: FDA-approved agents (tirzepatide, bremelanotide) rest on large-scale registration-quality trial data, while investigational peptides — epitalon, BPC-157, TB-500, Semax, GHK-Cu, CJC-1295, ipamorelin — show mechanistically interesting but methodologically limited signals, predominantly from preclinical models or small, often non-replicated studies.
The critical caveat is the design itself. Narrative reviews are synthesis without meta-analytic rigour; the 20-source selection pool is modest for a field this broad, and the review does not appear to have applied formal quality-grading criteria. Conclusions therefore reflect the authors' judgment rather than a systematic evidence synthesis.
For readers tracking investigational peptides: the review adds conceptual framing...
Plain-language abstract
This narrative review, published in Frontiers in Aging, set out to summarise what is currently known about therapeutic peptides that may support healthy aging — covering how they work, what clinical applications have been studied, what the evidence shows, and what safety data exist.
Researchers searched major scientific databases and regulatory records through January 2026 and selected 20 sources based on relevance and methodological quality. From those sources, they identified nine peptides targeting different aspects of aging: tirzepatide (metabolic function), epitalon (telomere biology), GHK-Cu (skin regeneration), BPC-157 and TB-500 (tissue repair), Semax (brain protection), CJC-1295 and ipamorelin (growth hormone signalling), and bremelanotide (sexual function).
The review found that FDA-approved peptides — tirzepatide and bremelanotide — are supported by robust data from large clinical trials. The remaining investigational peptides showed promising signals in preclinical or limited human studies, but the authors noted these lack long-term safety data and rigorous independent validation. The review identified several important knowledge gaps: optimal dosing is not established for most investigational peptides, effects of combining peptides are poorly understood, and reliable biomarkers for tracking outcomes do not yet exist.
The authors concluded that while therapeutic peptides offer diverse mechanistic approaches to aging biology, the investigational agents...